Astra Zeneca: A Merger That Beats Expectations

Astra Zeneca's stock performance may seem pedestrian at first glance, having outperformed the market by only 1%. However, a closer look at the company's financials reveals a more compelling picture. With a consolidated drugs business expected to generate $14 billion in sales and $3.5 billion in operating profits, Astra Zeneca's valuation looks attractive. The company's market capitalization of $75 billion can be largely explained by its drug business, which trades at a reasonable multiple of 25.

Key Takeaways:

• Astra Zeneca's stock has outperformed the market by 1% since the merger announcement, with sales expected to reach $14 billion and operating profits above $3.5 billion.
• The company's drugs business is expected to account for a significant portion of its $75 billion market capitalization, with a multiple of 25.
• The agreed-upon $1.1 billion savings from the merger will contribute to the valuation, as will the inclusion of Zeneca's agrochemicals and specialty chemicals businesses.
• Astra Zeneca's valuation is not as high as its competitor, Glaxo Wellcome, which trades at nearly 40 times multiples.
• The company faces risks related to patent expiries post-2000, but this risk is mitigated by the valuation multiple.
• Cross-border integration of research and development will be challenging due to national pride and competing interests.

Statistics:

• Astra Zeneca's stock has outperformed the market by 1%.
• Estimated sales for Astra Zeneca's consolidated drugs business: $14 billion.
• Estimated operating profits for Astra Zeneca's consolidated drugs business: $3.5 billion.
• Market capitalization: $75 billion.
• Multiple: 25.
• Expected savings from the merger: $1.1 billion.
• Sales of Astra Zeneca's market capitalization attributed to its drug business: $62.5 billion.

Sources:

• "Astra Zeneca" article, The Economist, no publication date provided.